Related Experiment Video
Updated: Jan 7, 2026
Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
Published on: December 23, 2022
Intratumoral Heterogeneity of MAGED4 Expression in Oral Squamous Cell Carcinoma: Epigenetic Mechanisms and
Huan Xie1, Feng Li1, Xiaoqiong Zou1
1Department of Histology and Embryology, School of Basic Medicine Science, Guangxi Medical University, Nanning 530021, China.
Abstract:
Intratumoral heterogeneity poses significant challenges to the efficacy of cancer immunotherapy. Melanoma-associated antigen D4 (MAGED4) has been proposed as a potential immunotherapeutic target in oral squamous cell carcinoma (OSCC). This study aims to investigate the expression of MAGED4, focusing on its intratumoral expression heterogeneity and the underlying epigenetic regulation mechanism. Utilizing public online databases, immunohistochemical analyses of clinical specimens, and single-cell RNA sequencing data, we found that MAGED4 was overexpressed with significant intratumoral heterogeneity in OSCC tissues. Methylation-promoter luciferase reporter assays revealed that MAGED4 transcription was suppressed by DNA methylation at its promoter region. Additionally, co-expression analysis implicated a potential role for histone acetylation in regulating MAGED4. To functionally validate these findings, we treated OSCC cells with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (DAC) and histone deacetylase inhibitors trichostatin A (TSA) and valproic acid (VPA). The triple-drug combination treatment resulted in the most robust reactivation of MAGED4 expression, correlating with promoter DNA demethylation and enhanced acetylation of H3K9 and H3K27 at the MAGED4 promoter. Our findings elucidate critical epigenetic mechanisms contributing to MAGED4 heterogeneity in OSCC and highlight the potential of combination epigenetic therapies to reverse this heterogeneity, thereby providing a foundation for exploring such approaches to improve immunotherapeutic outcomes.
Insights
Melanoma-associated antigen D4 (MAGED4) shows varied expression in oral cancer, driven by DNA methylation and histone changes. Combination epigenetic drugs can reverse this heterogeneity, improving immunotherapy potential.
Area of Science:
- Oncology
- Immunotherapy
- Epigenetics
Background:
- Intratumoral heterogeneity complicates cancer immunotherapy efficacy.
- Melanoma-associated antigen D4 (MAGED4) is a potential target in oral squamous cell carcinoma (OSCC).
Purpose of the Study:
- Investigate MAGED4 expression and its intratumoral heterogeneity in OSCC.
- Elucidate the epigenetic mechanisms regulating MAGED4 expression.
Main Methods:
- Analysis of public databases, immunohistochemistry, and single-cell RNA sequencing.
- Reporter assays to assess promoter methylation.
- Treatment of OSCC cells with epigenetic drugs (DAC, TSA, VPA).
Main Results:
- MAGED4 is overexpressed with significant intratumoral heterogeneity in OSCC.
- DNA methylation suppresses MAGED4 transcription; histone acetylation is also implicated.
- Combined epigenetic therapy demethylated the MAGED4 promoter and increased H3K9/H3K27 acetylation, reactivating MAGED4 expression.
Conclusions:
- Epigenetic mechanisms, including DNA methylation and histone acetylation, drive MAGED4 heterogeneity in OSCC.
- Combination epigenetic therapy can reverse MAGED4 heterogeneity.
- Reversing MAGED4 heterogeneity may enhance immunotherapy outcomes in OSCC.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
08:26MAME Models for 4D Live-cell Imaging of Tumor: Microenvironment Interactions that Impact Malignant Progression
Published on: February 17, 2012
